MedPath

Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis

Phase 3
Completed
Conditions
Necrotizing Enterocolitis
Interventions
Drug: Probiotic Formula
Registration Number
NCT06422000
Lead Sponsor
Tanta University
Brief Summary

The aim of this study is to evaluate the effectiveness of pentoxifylline versus probiotics supplementation as adjuvant therapy for preterm neonates with necrotizing enterocolitis.

Detailed Description

This randomized clinical trial includes 75 preterm infants who met the inclusion criteria for stage I and stage II NEC. Patients are allocated randomly into three groups (each included 25 neonates); group I (traditional therapy group) received antibiotics according to culture and sensitivity results, group II (pentoxifylline group) received antibiotics and IV pentoxifylline at a dose of 30 mg/ Kg given over 6 hours daily until discharge from the unit, and group III (probiotics group) received antibiotics and probiotics sachets supplementation in a dose of 100 mg mixed with 10 ml sterile water and given by Ryle tube once daily until discharge. The serum level of high-mobility group box protein 1 (HMGB-1), intestinal fatty acid binding proteins (I-FABP), and total antioxidant capacity (TAC) were measured on admission and at discharge.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Male and female preterm neonates less than 37 weeks gestational age
  • Suffering from necrotizing enterocolitis (NEC), according to Modified Bell's system which was first proposed by Bell et al., 1978 as stage I (suspected), II (proven) .
  • Diagnosis of NEC depends on; history, physical examination, laboratory and radiographic findings .
  • Signs and symptoms of NEC (at least three or more ), including; unstable temperature, apnea, increased residual milk in stomach, mid abdominal distension, vomiting coffee-like substances, bloody stool
  • Laboratory findings including; thrombocytopenia, hypernatremia, metabolic acidosis, neutropenia and leukocytosis.
  • Anterior posterior abdominal radiograph is used for diagnosis in which pneomatosis intestinalis in stage II NEC
Exclusion Criteria
  • Term and post term neonates
  • Neonates with congenital infections
  • Neonates with major congenital anomalies
  • Neonates with stage III NEC

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
probiotic group (group III)Probiotic Formulawill include 25 preterm neonates with NEC who will receive traditional therapy of NEC in association with probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
pentoxifylline group (group II)Pentoxifyllinewill include 25 preterm neonates with NEC who will receive traditional therapy of NEC in association with IV pentoxifylline at a dose of 30 mg/kg given over 6 hours daily (Schüller et al., 2020) until discharge from the unit after clinical and laboratory improvement .
Primary Outcome Measures
NameTimeMethod
Mortality rate2 months

record mortality rate in each group during treatment

Inflammatory parameter2 months

Change in serum C-reactive protein at baseline and after 2 months

complications and side effects2 months

record any complications or side effects of the treating drugs

Secondary Outcome Measures
NameTimeMethod
change in serum high-mobility group box protein 1 (HMGB1)2 months

blood sample will be collected at baseline and after 2 months

change in serum Intestinal fatty acid binding protein (I-FABP).2 months

blood sample will be collected at baseline and after 2 months

change in serum total antioxidant capacity (TAC)2 months

Blood sample will be collected at baseline and after 2 months

Trial Locations

Locations (1)

Tanta University

🇪🇬

Tanta, El Gharbia, Egypt

© Copyright 2025. All Rights Reserved by MedPath